A phase I clinical trial for malignant ascites is planned to initiate in China this year.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercialising biologic therapies, with a focus on oncology and autoimmune diseases.
Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways.
Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
Trimer-Tag© is a drug development platform which allows the production of novel, covalently-trimerized fusion proteins.
Many major disease targets are trimerization-dependent such as the tumor necrosis factor superfamily (involved in extrinsic apoptosis, immune co-stimulation and inflammation) as well as enveloped RNA virus antigens responsible for entry into host cells.
Clover is using Trimer-Tag© technology to create trimerized fusion proteins that are able to effectively target these previously undruggable pathways.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP